PMID- 37395510
OWN - NLM
STAT- MEDLINE
DCOM- 20230803
LR  - 20230807
IS  - 1531-6971 (Electronic)
IS  - 1070-5287 (Linking)
VI  - 29
IP  - 5
DP  - 2023 Sep 1
TI  - Interstitial lung disease in patients with anti-neutrophil cytoplasm 
      antibody-associated vasculitis: an update on pathogenesis and treatment.
PG  - 436-442
LID - 10.1097/MCP.0000000000000979 [doi]
AB  - PURPOSE OF REVIEW: Interstitial lung disease (ILD) is now recognized as a common 
      complication of anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitides 
      (AAV), especially myeloperoxidase (MPO)-ANCA-positive AAV and microscopic 
      polyangiitis (MPA). This review focuses on current concepts pertaining to the 
      pathogenesis, clinical assessment, and management of AAV-ILD. RECENT FINDINGS: 
      ILD is typically identified before or at the onset of systemic AAV, and usual 
      interstitial pneumonia (UIP) is the most common CT pattern. MPO-ANCA production, 
      neutrophil extracellular traps formation, reactive oxidative species production, 
      complement activation, environmental exposures, and genetic background might play 
      a role in the pathogenesis of AAV-ILD. Recent research has identified promising 
      biomarkers as potential diagnostic and prognostic tools in AAV-ILD. The optimal 
      treatment for AAV-ILD is not well defined but might rely on a combination of 
      immunosuppression and antifibrotics, especially in patients with progressive lung 
      fibrosis. Despite the effectiveness of current therapies for AAV, the outcome of 
      patients with AAV-ILD remains poor. SUMMARY: ANCA screening should be considered 
      in patients with newly diagnosed ILD. Management of AAV-ILD should be overviewed 
      by a collaborative team comprising vasculitis experts and respirologists. VIDEO 
      ABSTRACT: http://links.lww.com/COPM/A33.
CI  - Copyright (c) 2023 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Turgeon, David
AU  - Turgeon D
AD  - Vasculitis Clinic, Division of Rheumatology.
FAU - Balter, Meyer S
AU  - Balter MS
AD  - Division of Respirology, Mount Sinai Hospital, University of Toronto, Toronto, 
      Ontario, Canada.
FAU - Pagnoux, Christian
AU  - Pagnoux C
AD  - Vasculitis Clinic, Division of Rheumatology.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Video-Audio Media
DEP - 20230630
PL  - United States
TA  - Curr Opin Pulm Med
JT  - Current opinion in pulmonary medicine
JID - 9503765
RN  - 0 (Antibodies, Antineutrophil Cytoplasmic)
RN  - 0 (Biomarkers)
SB  - IM
MH  - Humans
MH  - Antibodies, Antineutrophil Cytoplasmic
MH  - *Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/complications/therapy
MH  - *Lung Diseases, Interstitial/diagnosis/etiology/therapy
MH  - Biomarkers
MH  - Cytoplasm/pathology
EDAT- 2023/07/03 13:06
MHDA- 2023/08/03 06:43
CRDT- 2023/07/03 08:23
PHST- 2023/08/03 06:43 [medline]
PHST- 2023/07/03 13:06 [pubmed]
PHST- 2023/07/03 08:23 [entrez]
AID - 00063198-202309000-00014 [pii]
AID - 10.1097/MCP.0000000000000979 [doi]
PST - ppublish
SO  - Curr Opin Pulm Med. 2023 Sep 1;29(5):436-442. doi: 10.1097/MCP.0000000000000979. 
      Epub 2023 Jun 30.